Search

everythinglearnresearchcommunity

for

Search:↓

Increased regulatory T cell activity may lead to better outcomes in acute diffuse and total alopecia.

The document explains how the immune system reacts to organ transplants and the treatments used to prevent rejection.

FOXN1 is crucial for thymus development and immune response in Xenopus laevis.

Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.

Different types of hair loss have unique cellular changes, suggesting new treatment targets.

The nodule was a benign cutaneous lymphadenoma, not cancer, and was successfully removed.

Cyclosporine effectively treated a woman's stubborn skin condition.

CD8+ virtual memory T cells may cause hair loss in alopecia areata.

Kang-ai injection with platinum-based chemotherapy improves tumor response and immune function while reducing side effects in advanced lung cancer.

Ebastine may help regrow hair in alopecia areata patients.

Alopecia areata involves persistent gene abnormalities and immune activity, even in regrown hair, suggesting a risk of relapse.

Early treatment with the right dose of stem cells can reduce lupus symptoms.

Folate receptor β helps suppress the immune system in macrophages and affects cancer growth and hair health.

Radiation therapy damages skin structure and immune function, causing inflammation and potential hair loss.

Psoriasis involves immune and genetic factors, and understanding these can improve treatments.

Pertussis toxin may contribute to hair loss in alopecia areata.

CAR-T therapy offers hope for children with hard-to-treat blood cancers.

New treatments targeting the JAK signaling pathway, especially JAK inhibitors, show promise for alopecia areata.

Scientists are still unsure what triggers the immune system to attack hair follicles in Alopecia areata.

Scalp involvement in primary cutaneous lymphomas is common and can be aggressive, requiring careful attention.

The 2004 hair research meeting presented new findings on hair cell differentiation, genetic factors in hair loss, hair pigmentation, and potential targeted therapies.

PPAR-γ agonists like pioglitazone may help manage lichen planopilaris but don't fully reverse scarring.

Gamma delta T cells in the skin help with healing and defense but can also cause autoimmune issues, and more research is needed to understand how they are activated.

Early regulatory T cells are crucial for normal skin pigmentation.

BAFF-targeted therapies can reduce autoimmune disease activity, but more research is needed for precise treatments.

The conditions alopecia areata, primary sclerosing cholangitis, and ulcerative colitis may be linked by shared autoimmune and cell death mechanisms.

Special cells can help regrow hair in alopecia areata.

Using fat-derived stem cells with the drug meglumine antimoniate can help control skin disease and reduce parasites in mice with leishmaniasis.

OX40-targeted therapies may help treat skin diseases by reducing inflammation and balancing immune responses.

Dogs have a skin condition like human pseudopelade, causing hair loss that doesn't improve with treatment.